Moors & Cabot’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.8M | Buy |
70,717
+426
| +0.6% | +$91.7K | 0.69% | 27 |
|
|
2026
Q1 | $15.3M | Buy |
70,291
+1,466
| +2% | +$325K | 0.65% | 30 |
|
|
2025
Q4 | $15.7M | Buy |
68,825
+517
| +0.8% | +$118K | 0.67% | 26 |
|
|
2025
Q3 | $15.8M | Buy |
68,308
+2,575
| +4% | +$524K | 0.69% | 28 |
|
|
2025
Q2 | $12.2M | Sell |
65,733
-815
| -1% | -$151K | 0.57% | 38 |
|
|
2025
Q1 | $13.9M | Buy |
66,548
+1,041
| +2% | +$202K | 0.71% | 27 |
|
|
2024
Q4 | $11.6M | Buy |
65,507
+581
| +0.9% | +$107K | 0.55% | 39 |
|
|
2024
Q3 | $12.8M | Sell |
64,926
-2,683
| -4% | -$501K | 0.64% | 29 |
|
|
2024
Q2 | $11.6M | Sell |
67,609
-3,204
| -5% | -$531K | 0.62% | 31 |
|
|
2024
Q1 | $12.9M | Buy |
70,813
+140
| +0.2% | +$24.1K | 0.7% | 26 |
|
|
2023
Q4 | $11M | Sell |
70,673
-1,223
| -2% | -$178K | 0.68% | 25 |
|
|
2023
Q3 | $10.7M | Buy |
71,896
+2,534
| +4% | +$372K | 0.73% | 23 |
|
|
2023
Q2 | $9.35M | Sell |
69,362
-1,988
| -3% | -$292K | 0.62% | 29 |
|
|
2023
Q1 | $11.4M | Buy |
71,350
+69
| +0.1% | +$10.5K | 0.78% | 21 |
|
|
2022
Q4 | $11.5M | Sell |
71,281
-95
| -0.1% | -$14.6K | 0.8% | 19 |
|
|
2022
Q3 | $9.58M | Sell |
71,376
-1,480
| -2% | -$212K | 0.73% | 20 |
|
|
2022
Q2 | $11.2M | Sell |
72,856
-1,904
| -3% | -$291K | 0.8% | 20 |
|
|
2022
Q1 | $12.1M | Sell |
74,760
-3,269
| -4% | -$475K | 0.75% | 20 |
|
|
2021
Q4 | $10.6M | Buy |
78,029
+2,816
| +4% | +$333K | 0.65% | 26 |
|
|
2021
Q3 | $8.13M | Buy |
75,213
+7,351
| +11% | +$840K | 0.51% | 36 |
|
|
2021
Q2 | $7.64M | Buy |
67,862
+536
| +0.8% | +$60.4K | 0.54% | 38 |
|
|
2021
Q1 | $7.29M | Buy |
67,326
+4,101
| +6% | +$439K | 0.56% | 36 |
|
|
2020
Q4 | $6.78M | Buy |
63,225
+6,243
| +11% | +$600K | 0.57% | 37 |
|
|
2020
Q3 | $4.99M | Buy |
56,982
+5,696
| +11% | +$536K | 0.47% | 50 |
|
|
2020
Q2 | $5.04M | Buy |
51,286
+7,897
| +18% | +$695K | 0.54% | 42 |
|
|
2020
Q1 | $3.3M | Buy |
43,389
+1,018
| +2% | +$86.7K | 0.48% | 49 |
|
|
2019
Q4 | $3.75M | Sell |
42,371
-218
| -0.5% | -$18.1K | 0.38% | 65 |
|
|
2019
Q3 | $3.23M | Buy |
42,589
+6,960
| +20% | +$477K | 0.36% | 72 |
|
|
2019
Q2 | $2.6M | Buy |
35,629
+1,716
| +5% | +$135K | 0.33% | 79 |
|
|
2019
Q1 | $2.73M | Sell |
33,913
-3,788
| -10% | -$310K | 0.37% | 74 |
|
|
2018
Q4 | $3.47M | Sell |
37,701
-14,488
| -28% | -$1.27M | 0.54% | 43 |
|
|
2018
Q3 | $4.93M | Buy |
52,189
+1,776
| +4% | +$168K | 0.6% | 35 |
|
|
2018
Q2 | $4.67M | Sell |
50,413
-2,301
| -4% | -$225K | 0.63% | 32 |
|
|
2018
Q1 | $4.99M | Buy |
52,714
+2,388
| +5% | +$262K | 0.66% | 27 |
|
|
2017
Q4 | $4.87M | Buy |
50,326
+2,293
| +5% | +$216K | 0.64% | 31 |
|
|
2017
Q3 | $4.27M | Buy |
48,033
+18,697
| +64% | +$1.42M | 0.62% | 30 |
|
|
2017
Q2 | $2.13M | Sell |
29,336
-733
| -2% | -$49.3K | 0.35% | 75 |
|
|
2017
Q1 | $1.97M | Sell |
30,069
-532
| -2% | -$33.4K | 0.33% | 84 |
|
|
2016
Q4 | $1.92M | Sell |
30,601
-944
| -3% | -$57.6K | 0.32% | 84 |
|
|
2016
Q3 | $2M | Sell |
31,545
-328
| -1% | -$21.2K | 0.33% | 75 |
|
|
2016
Q2 | $1.96M | Sell |
31,873
-443
| -1% | -$27K | 0.34% | 72 |
|
|
2016
Q1 | $1.84M | Buy |
32,316
+1,525
| +5% | +$85K | 0.33% | 76 |
|
|
2015
Q4 | $1.83M | Sell |
30,791
-1,767
| -5% | -$102K | 0.34% | 78 |
|
|
2015
Q3 | $1.77M | Sell |
32,558
-5,774
| -15% | -$376K | 0.33% | 78 |
|
|
2015
Q2 | $2.58M | Buy |
38,332
+3,340
| +10% | +$218K | 0.42% | 64 |
|
|
2015
Q1 | $2.06M | Buy |
34,992
+1,962
| +6% | +$119K | 0.34% | 79 |
|
|
2014
Q4 | $2.17M | Buy |
33,030
+1,045
| +3% | +$65.9K | 0.37% | 71 |
|
|
2014
Q3 | $1.86M | Buy |
31,985
+1,639
| +5% | +$91K | 0.32% | 80 |
|
|
2014
Q2 | $1.71M | Buy |
30,346
+4,452
| +17% | +$234K | 0.29% | 89 |
|
|
2014
Q1 | $1.33M | Buy |
+25,894
| New | +$1.31M | 0.34% | 80 |
|
Other funds holding ABBV
Moors & Cabot's ABBV Position: Q2 2026 in Review
Moors & Cabot increased its AbbVie (ABBV) stake by 0.61% in Q2 2026, buying an estimated $91.7K and bringing the position to 70,717 shares worth $17.8M. The position accounts for 0.69% of the portfolio, ranked #27.
Moors & Cabot first reported a position in ABBV in Q1 2014 and has held it in 50 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Moors & Cabot held 70,717 shares of AbbVie worth $17.8M as of Q2 2026.
- Moors & Cabot bought 426 AbbVie shares in Q2 2026, an estimated $91.7K.
- AbbVie made up 0.69% of Moors & Cabot's portfolio in Q2 2026, its #27 holding.
- Moors & Cabot first reported a position in AbbVie in Q1 2014 and has held it in 50 quarters since.
- 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.